These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 28223229)
1. Theranostic of biopharmaceuticals. Chaigne B; Watier H Pharmacol Ther; 2017 Jul; 175():67-74. PubMed ID: 28223229 [TBL] [Abstract][Full Text] [Related]
2. Infections associated with monoclonal antibody and fusion protein therapy in humans. Uettwiller F; Rigal E; Hoarau C MAbs; 2011; 3(5):461-6. PubMed ID: 21822056 [TBL] [Abstract][Full Text] [Related]
3. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659 [TBL] [Abstract][Full Text] [Related]
4. Harnessing Fc receptor biology in the design of therapeutic antibodies. Sondermann P; Szymkowski DE Curr Opin Immunol; 2016 Jun; 40():78-87. PubMed ID: 27038127 [TBL] [Abstract][Full Text] [Related]
5. Variability factors in the clinical response to recombinant antibodies and IgG Fc-containing fusion proteins. Watier H Expert Opin Biol Ther; 2005 Sep; 5 Suppl 1():S29-36. PubMed ID: 16187938 [TBL] [Abstract][Full Text] [Related]
6. Fcγ1 fragment of IgG1 as a powerful affinity tag in recombinant Fc-fusion proteins: immunological, biochemical and therapeutic properties. Soleimanpour S; Hassannia T; Motiee M; Amini AA; Rezaee SA Crit Rev Biotechnol; 2017 May; 37(3):371-392. PubMed ID: 27049690 [TBL] [Abstract][Full Text] [Related]
7. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. Moreland LW; Baumgartner SW; Schiff MH; Tindall EA; Fleischmann RM; Weaver AL; Ettlinger RE; Cohen S; Koopman WJ; Mohler K; Widmer MB; Blosch CM N Engl J Med; 1997 Jul; 337(3):141-7. PubMed ID: 9219699 [TBL] [Abstract][Full Text] [Related]
10. Advances in the assessment and control of the effector functions of therapeutic antibodies. Jiang XR; Song A; Bergelson S; Arroll T; Parekh B; May K; Chung S; Strouse R; Mire-Sluis A; Schenerman M Nat Rev Drug Discov; 2011 Feb; 10(2):101-11. PubMed ID: 21283105 [TBL] [Abstract][Full Text] [Related]
11. [Immunogenicity of biopharmaceuticals: Which consequences during the treatment of rheumatoid arthritis?]. Goupille P Rev Med Interne; 2016 May; 37(5):343-9. PubMed ID: 26526777 [TBL] [Abstract][Full Text] [Related]
12. Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization. Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Johnson S; Koenig S; Bonvini E Adv Enzyme Regul; 2008; 48():152-64. PubMed ID: 18177741 [No Abstract] [Full Text] [Related]